New study finds that nasal cells protect against Covid-19 in children

18 Apr 2024, 9:20 a.m.

Human nasal cells cultured in a petri dish

New research shows that children are less likely than adults to develop severe COVID because cells in their nose are better at fighting off the virus.

The research, by UCL and the Wellcome Sanger Institute, found that there are significant differences in how the nasal cells of young and elderly people respond to COVID, which could explain why children typically experience milder symptoms.

Researchers grew nasal cells taken from the nose lining of healthy people from three different age groups: under 12, 30 to 50 year olds, and over 70's. They then infected these cells with COVID.

The cells taken from children were quick to defend against the virus however this protective effect became less pronounced with age. They also found that the nose cells from the over-70s showed more virus and more damage and shedding in the cells.

Children infected with COVID rarely progress to respiratory failure, but the risk of mortality in people over the age of 85 remains high, despite vaccination and improving treatment options.

The research underscores the importance of considering age as a critical factor in both research and treatment of infectious diseases.

Project lead, Dr Claire Smith (Associate Professor at UCL Great Ormond Street Institute of Child Health), said:

“Our research sheds light on how age affects the ability of our nasal cells to combat SARS-CoV-2 infection. This could be crucial in developing age-tailored treatments and preventative strategies, especially for the elderly who at higher risk of severe disease.”

The research was carried out by UCL and the Wellcome Sanger Institute, and funded by UK Research and Innovation, the NIHR Great Ormond Street Hospital Biomedical Research Centre and the Chan Zuckerberg Foundation.

Engineered tissue offers hope for children born with ‘missing’ food pipe

Scientists from Great Ormond Street Hospital (GOSH) and University College London (UCL) have created the first lab‑grown oesophagus - the food pipe - shown to safely replace a full section of the organ and restore normal function, including swallowing, in

GOSH celebrates Rare Disease Day 2026 with local community

GOSH specialises in rare disease research and to celebrate, we recently invited two local North London Year 4 classes to join us for the day to learn about how we care for patients with rare diseases.

Professor Francesco Muntoni wins prestigious research prize

Professor Francesco Muntoni, GOSH Paediatric Neurology Consultant, has been awarded the 2026 Novo Nordisk Prize in recognition of his pioneering work transforming the outlook for children with Duchenne muscular dystrophy (DMD).

GOSH secures £1.4m in NIHR capital equipment funding to boost research capability

This investment will significantly strengthen our research infrastructure and enhance our ability to deliver world‑leading paediatric research across the whole hospital.